朗科科技(300042.SZ):董事鄧國順再次減持1.4036%的股份
格隆匯 11 月 1日丨朗科科技(300042.SZ)公佈,公司於2020年9月2日披露了《關於持股5%以上股東股份減持比例超過1%的公告》,減持期間內,鄧國順以集中競價交易和大宗交易方式累計減持公司股份213.5萬股,減持股份佔公司股本總數的比例1.0654%;此次變動後,鄧國順持有公司股份3843.4萬股,佔本公司總股本比例19.1786%。
公司於2020年10月30日收到持股5%以上股東、董事鄧國順出具的《股份減持統計》,獲悉其通過集中競價和大宗交易方式減持公司股份共計281.29萬股,佔公司總股本的1.4036%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.